Trial Profile
A study to determine the optimal dose of Tarceva [erlotinib], in combination with irinotecan and Xeloda [capacitabine], as second line therapy in patients with metastatic colorectal cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Feb 2010
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Erlotinib (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Roche
- 10 Jan 2008 Status change
- 29 May 2007 New trial record.